News

Bristol-Myers Squibb (BMY) stock is drawing attention after recent trading performance, with shares closing at US$55.28. Investors are weighing this level against the company’s mixed growth profile across revenue, earnings and longer term returns. See our latest analysis for Bristol-Myers Squibb. Recent trading has been a bit soft, with a 30 day share price return down 3.54% and a 90 day return down 4.87%. However, the 1 year total shareholder return of 23.92% shows that longer term holders...

Bristol Myers Squibb (NYSE:BMY) reported positive Phase III SUCCESSOR-2 trial results in multiple myeloma at a major medical conference. The company highlighted early clinical success for a new CAR T-cell therapy targeting blood cancers. Bristol Myers Squibb appointed a new General Manager to lead its operations across the Gulf region. Bristol Myers Squibb is a large biopharmaceutical company with a long-standing focus on oncology and hematology treatments. The fresh readout from the...

The latest trading day saw Bristol Myers Squibb (BMY) settling at $55.28, representing a -1.14% change from its previous close.

CYTK has gained 18.4% YTD as Myqorzo's FDA approval, early launch momentum, and expanding market opportunities fuel investor interest.

IMCR is seeing strong Kimmtrak sales growth and pursuing label expansion studies that could broaden its reach across melanoma treatments.

Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.

Bristol Myers Squibb (BMS) has revealed clinical data for two pipeline candidates in multiple myeloma (MM) at the European Hematology Association Congress (EHA) 2026, held from June 11–14. While the drugmaker already has multiple therapies approved for the type of blood cancer, BMS is hoping to expand its presence in the market by addressing certain…

Bristol Myers eyes growth from Camzyos as the FDA reviews its use in adolescents with obstructive HCM, expanding the drug's market reach.

Edgewise Therapeutics shares yo-yoed Tuesday as investors compared the results of its experimental heart disease treatment to approved drugs.

They have a habit of consistently raising their payouts.

Most Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) owners assume they are buying broad market diversification. The latest Schwab fact sheet tells a different story. SCHD’s top 10 holdings now account for 41% of the fund’s $71.6 billion in net assets, well above the roughly 30% top-10 weight typical of large-cap dividend peers. SCHD still earns ... SCHD Now Concentrates 42 Percent of Your Money in Just 10 Stocks. Here Is Who Should Still Own It

With the 10-Year Treasury yielding 4.48% and the Fed signaling more cuts ahead, income investors are hunting for yield that compounds. Bristol Myers Squibb (NYSE:BMY) offers a 4.39% yield backed by 94 consecutive years of dividend payments. The pharma giant is rebuilding around a Growth Portfolio (Eliquis, Camzyos, Breyanzi) while legacy drugs face generic erosion. ... A Dramatic Shift in Fed Policy Just Unlocked a New Era for Bristol Myers Squibb

The S&P 500 index is removing Pool Corp and Campbell Soup, replacing them with Marvell Technology and Flex. The team discusses what this means for investors.

Bristol Myers Squibb has a well-above-market yield of 4.5% and it appears reasonably safe.

BMY's growth portfolio now drives more than half of revenues, with strong gains from Reblozyl, Breyanzi and Cobenfy helping offset legacy drug declines.

Bristol Myers Squibb (NYSE:BMY) is rolling out an AI driven overhaul of its procurement operations, using tools designed to shorten sourcing timelines and reshape internal buying processes. The company is also expanding its oncology footprint through a new non exclusive clinical collaboration with Arcus Biosciences that focuses on late stage cancer drug trials. These developments come alongside earlier attention on product approvals, clinical milestones, and access programs, which have...

Bristol Myers Squibb (BMY) closed at $56.87 in the latest trading session, marking a +2.28% move from the prior day.

"Productivity initiatives" could prove key in maintaining this pharma company's decades-long dividend growth streak.

Takeda said Thursday its AI-designed psoriasis pill, zasocitinib, easily beat Bristol's Sotyktu in a head-to-head study.

The results support Takeda’s long-held belief in zasocitinib’s superiority and could help it gain a commercial advantage over Bristol’s therapy.

Bristol Myers Squibb Foundation, linked to NYSE:BMY, is rolling out a new lung cancer detection and care model in underserved Brazilian communities. The program uses mobile CT units, telemedicine, and local community engagement to support earlier diagnosis and access to curative treatment. This initiative focuses on healthcare equity and may offer a template that could be applied to other regions over time. For investors following NYSE:BMY, this move extends the story beyond drug pipelines...

Earned income has a ceiling. Hours in a day, headcount budgets, layoff cycles, and corporate restructurings all cap how much a paycheck can deliver. Passive income flips that dynamic. A properly built dividend portfolio pays you on a schedule independent of whether you showed up to work or whether your employer hit its quarter. Real ... Earn $5,000+ Yearly With These 4 Dividend Stocks

BioNTech SE (NASDAQ:BNTX) is one of the best healthcare stocks to buy with highest upside potential. BioNTech SE (NASDAQ:BNTX) and Bristol Myers Squibb Company announced on May 30 interim Phase 2 data from the global Phase 2/3 ROSETTA Lung-02 clinical trial evaluating the investigational PD-L1xVEGF-A bispecific immunomodulator pumitamig plus chemotherapy in patients with previously untreated advanced […]

The pharmaceutical giant cut procurement timelines from months to weeks while challenging conventional wisdom on AI data readiness.

SNY wins EU approval for a subcutaneous Sarclisa option in multiple myeloma, offering faster administration and flexible delivery methods.

The biotech giant is bucking the market trend, but its real value for investors lies in a story that unfolds over years, not days.

Argenx (ARGX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

The drugmaker's recent outperformance is a sideshow to its more valuable, long-term trait for investors.

Bristol Myers Squibb (NYSE:BMY) is the headline pharma name dividend hunters keep circling, drawn in by a 4.37% yield and a forward P/E of 9 that screams cheap. But the underlying numbers tell a different story. That low multiple is cheap for a reason. Bristol Myers is running headfirst into a generic cliff that the ... Forget Wall Street’s Ultimate Pharma Value Trap: Here Is a Far Better Stock to Buy Right Now

A 63-year-old retiree with $400,000 parked in the Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) likely picked it for the 100-stock screen and the reliable income stream. The top 10 positions now make up 41% of the fund, which means roughly $164,000 of that nest egg sits in ten names. For a fund managing $94 billion, ... SCHD’s $85 Billion Strategy Now Concentrates 41 Percent of Your Money in Just Ten Stocks